13. IAS Konferenz in Kigali
Die Konferenz fand nicht nur in Afrika statt, sie stand auch ganz im Zeichen von HIV in Afrika. Viele Arbeiten
beschäftigten sich mit den Auswirkungen der finanziellen Kürzungen, der Zukunft der Prävention und den Effekten der ART
im afrikanischen Setting. Darüber hinaus wurden aber auch neue Medikamente, Kohorten-Auswertungen und neue Leitlinien
vorgestellt. Ein Bericht über den Kongress erscheint in Infection&more
3/2025
PDF/PPT zum
Download 
Gilead
Abstracts HIV - IAS 2025 – Internal Datasets
B/F/TAF | |
| Long-term Persistence, Effectiveness, Safety, and Metabolic Impact of B/F/TAF Fixed-Dose Combination in TN and Experienced PWH in a Large Latin American Cohort | BFTAF/Cecchini_IAS2025_Poster_EP0173.pdf |
| Real-World Liver Outcomes in PWH and Hepatitis B Virus Receiving ART | BFTAF/Chuo_IAS2025_Poster_WEPEC045.pdf |
| HIV viewpoints: Survey on the Experiences of PWH Around the World | BFTAF/Guillaume_IAS2025_Poster_THPED077.pdf |
F/TAF | |
| Efficacy and Safety of F/TAF plus Cobicistat BPI in Children with HIV-1 Aged 2-<12 Years and Weighing 14-<40 kg: Week 48 Outcomes | FTAF/Mujuru_IAS2025_Poster_TUPEB041.pdf |
PREVENTION | |
| Lenacapavir Dosing in Special Situations: Tuberculosis and Beyond | Prevention/Bekker_IAS2025_Oral LB.pdf |
| Inclusion of Pregnant and Lactating People in the Purpose 1 Study: Efficacy, Safety, and PK | Prevention/Bekker_IAS2025_Oral_C0504.pdf |
| Protecting Mothers and Babies From HIV: Lessons From the PURPOSE 1 Study of Lenacapavir for PrEP | Prevention/Bekker_Summary_IAS2025_Summary_Final_draft_15July25_Unedit.pdf |
| Efficacy, Safety, and PK of Twice-Yearly Subcutaneous Lenacapavir for Prep Among Adolescents and Young People in the Phase 3 Trials PURPOSE 1 and PURPOSE 2 | Prevention/Gill_IAS2025_Oral_C0503.pdf |
| Protecting Young People From HIV: Lessons From the PURPOSE 1 and 2 Studies of Lenacapavir for PrEP | Prevention/Gill_Summary_IAS2025_P1_P2_Young_people__Final_draft_15Jul.pdf |
| Estimation of the Counterfactual HIV Incidence in the PURPOSE Trials | Prevention/Kelley_IAS2025_Oral_C0505.pdf |
| Predictors of HIV Prep Preferences Using the Health Belief Model: Twice-Yearly Subcutaneous Lenacapavir vs Daily Pills in the PURPOSE 1 Trial | Prevention/Mansoor_IAS2025_Poster_TUPEC057.pdf |
| Preference for Twice-Yearly Injections vs Daily Oral Pills for HIV Prep in Cisgender Men, Transgender Women, Transgender Men, and Gender Nonbinary People Enrolled in PURPOSE 2 | Prevention/Mngadi_IAS2025_Oral_C0502.pdf |
| Exploratory Qualitative Analysis of the Acceptability of HIV Prevention Methods Among Pregnant and Lactating Women Interviewed During the Randomized Blinded Phase of PURPOSE 1 | Prevention/Nyamaizi_IAS2025_Poster_EP0725.pdf |
| Factors Impacting Women's Choice of Prep use After the Randomized Blinded Phase of PURPOSE 1 | Prevention/Palanee-Phillips_IAS2025_Poster_WEPED077.pdf |
LEN HIV TREATMENT PIPELINE: LEN + bNAbs | |
| HIV-Specific T-cell Responses in Suppressed PWH Receiving Lenacapavir, Teropavimab, and Zinlirvimab | LEN HIV Tx Pipeline LEN+bNAbs/Cai_IAS2025_Oral_OAA0205.pdf |
| Satisfaction, Preference, and Health-Related Quality of Life Changes Using HIV-Specific PRO Measures with a Novel, Twice-Yearly Administered HIV-1 Treatment Regimen | LEN HIV Tx Pipeline LEN+bNAbs/Gaur A_IAS 2025_Poster_THPEB038.pdf |
HIV CURE | |
| Vesatolimod Pharmacodynamic Responses in a Trial of Vesatolimod and bNAbs in Early-Treated South African Women with Clade C HIV-1 | HIV Cure/Cai_IAS2025_Poster_WEPEB018.pdf |
| Synergizing Expertise: Lessons Learned from Conducting the first HIV Cure Interventional Trial in Africa with Collaboration Between Academia, Government, and Industry | HIV Cure/Dong_IAS2025_Poster_EP1003.pdf |
HIV TREATMENT (OTHER) | |
| Biomarkers Associated with Risk of Negative Clinical Outcomes in PWH on Opioid Replacement Therapy | HIV Tx other/Azzoni_IAS2025_Poster_EP0081.pdf |
B/F/TAF | |
| Predictors of Weight Gain among PWH Over 3-year Period | BFTAF/Elion_IAS2025_Oral_OAB0204.pdf |
| Evaluating Social Support, Psychological Distress, and HIV-Related Stigma in a Cohort of ART-Experienced Migrants Switched to B/F/TAF in Montreal, Canada - the ASAP-Switch Study | BFTAF/Godin_IAS2025_Poster_EP0239.pdf |
| Co-morbidities in HIV Positive and HIV NegativeIndividuals Aged ≥60 Years - A Comparative Analysis | BFTAF/Ombajo_IAS2025_Poster_TUPEB021.pdf |
LENACAPAVIR HIV TREATMENT | |
| Capsid Inhibition with Lenacapavir in HIV-1 Infection: Real-Life Results From the French Compassionate Use Program | LEN HIV Tx/Delaugerre_IAS2025_Poster_EP0195.pdf |
HIV PREVENTION/PrEP | |
| "It Seemed Like Something I Couldn't Really Ask for:" A Qualitative Analysis of Cis- and Transgender Women's Experiences Along the PrEP Cascade in the South Bronx, NYC | HIV Prevention PrEP/Abularrage_IAS2025_Poster_EP0529.pdf |
| Prescription of HIV Pre-Exposure Prophylaxis and HIV Incidence in a Cohort of Women with Severe Mental Illnesses in the U.S. | HIV Prevention PrEP/Bunting_IAS2025_Poster_EP0337.pdf |
| Differential HIV Incidence and PrEP-to-Need Ratio Among a Large, Diverse Cohort of People With Mental Illnesses in the U.S. | HIV Prevention PrEP/Bunting_IAS2025_Poster_TUPEC053.pdf |
| HIV Incidence and Use of Pre-Exposure Prophylaxis Among a Large, National Cohort of People with Bipolar Disorder | HIV Prevention PrEP/Bunting_IAS2025_Poster_WEPEC053.pdf |
| Making PrEP Smart: Persistence, Use, and Acceptability of a PrEP Adherence and HIV-Self Testing App Among Women in the South Bronx, NYC | HIV Prevention PrEP/Wright_IAS2025_Poster_EP0866.pdf |
ViiV Healthcare
|
CABOTEGRAVIR + RILPIVIRINE Long-acting for treatment |
|
|
Perspectives of healthcare providers on long-acting injectable cabotegravir and rilpivirine
delivery in clinic and community settings in the UK: longitudinal survey findings from the ILANA study* |
|
|
The power of choice: strong preference for CAB+RPV LA following rapid suppression with
DTG/3TC in newly diagnosed people living with HIV |
|
|
Real-world Effectiveness of CAB+RPV LA in Individuals with HIV Viremia at Therapy
Initiation |
|
|
Clinical Outcomes Among Women in the OPERA Cohort Initiating CAB+RPV LA with Viral Loads ≥ 50
copies/mL |
|
|
High virologic suppression and few virologic failures with Long-Acting Cabotegravir +
Rilpivirine in Treatment Experienced Virologically Suppressed Individuals from COMBINE-2 cohort in Europe |
|
|
Perspectives of people with HIV (PWH) 24 months following a switch to cabotegravir and
rilpivirine long-acting (CAB+RPV LA) in an observational real-world US study (BEYOND) |
|
|
Clinical Outcomes at Month 24 After Initiation of Cabotegravir and Rilpivirine Long Acting
(CAB+RPV LA) in an Observational Real-World Study (BEYOND) |
|
|
24-month outcomes of cabotegravir+rilpivirine long-acting every 2 months in a real-world
setting: effectiveness, adherence to injections, and participant-reported outcomes from people with HIV-1 in the German
CARLOS cohort |
|
|
Pregnancy and Neonatal Outcomes Following Prenatal Exposure to Cabotegravir (CAB): Data from
The Antiretroviral Pregnancy Registry (APR) |
|
|
DOLUTEGRAVIR-based regimens |
|
|
Virological outcomes of adolescents switched to dolutegravir based regimens at
Botswana-Baylor Children's Clinical Centre of Excellence (BBCCCOE), 2016 to 2023* |
|
|
Predictors of treatment failure in children living with HIV starting first-line
antiretroviral therapy in the ODYSSEY trial* |
|
|
Efficacy of dolutegravir plus lamivudine in treatment-naïve people with HIV with baseline
transmitted drug-resistance mutations: a subanalysis of the D2ARLING study* |
|
|
Patient-Reported Outcomes among virally suppressed people living with HIV switching to
dolutegravir/lamivudine vs. continuing bictegravir/emtricitabine/tenofovir alafenamide from the randomized DYAD study*
|
|
|
Impact of Dual Therapy on Weight Gain and Metabolic Outcomes in Naïve People living with HIV
(PLHIV) with CD4 Counts <200 Cells/mm3: Findings from the DOLCE Study* |
|
|
The Impact of Immune Reconstitution Inflammatory Syndrome (IRIS) in HIV-Positive People with
CD4 <200 Cells/mm3 Initiating Dolutegravir/Lamivudine Dual Therapy: DOLCE Study Findings* |
|
|
Is exclusion of tenofovir from antiretroviral regimens safe in Africa: insights on hepatitis
B from the switch to DTG/3TC (Sungura) study* |
|
|
Efficacy and safety of switching to dolutegravir/lamivudine dual therapy from
bictegravir/emtricitabine/tenofovir alafenamide among virally suppressed older adults ≥60 years: week 24 results from
the Sungura study* |
|
|
Rapid virologic suppression with DTG/3TC facilitates early switch to CAB+RPV LA for
treatment-naive people living with HIV: Suppression Phase outcomes from the Phase 3b VOLITION study |
|
*denotes ViiV-supported investigator led and collaborative studies
| |
|
Über den untenstehenden Link erhalten Sie Zugriff auf alle von ViiV gesponserten sowie von ViiV-unterstützten Kooperationsstudien, die beim IAS 2025 präsentiert wurden – darunter auch Studien zu Cabotegravir zur Prävention und weitere HIV-bezogene Publikationen. |
| |
|
|
Kollegen Fragen
Diese Seite weiter empfehlen
